allegro
Pioneering a Cure for Osteoarthritis

Osteoarthritis, a chronic and degenerative joint ailment affecting one-third of individuals over age 65, is poised to get a potential cure within the dynamic field of biopolymers in the continuously advancing life sciences landscape.

Allegro, an innovative company dedicated to advancing biomedical technologies in rheumatology and orthopedics, is leading the way in this promising field. With its truckloads of expertise, knowledge, and cutting-edge technology, it is poised to revolutionize osteoarthritis treatment, offering hope for improved solutions beyond traditional pain management.

Osteoarthritis is characterized by excessive wear and tear on the joints, leading to pain and disability. This burden of this ailment can profoundly impact every facet of one’s daily life, from their job and family to leisure activities. For many years, those afflicted with osteoarthritis have been left with inadequate treatment options, often relying solely on painkillers or, in some cases, hyaluronic acid injections.

“Treating a physical ailment with painkillers is akin to masking the warning light in your car with a sticker rather than addressing the root cause,” says Lucas Decuypere, CEO at Allegro. “What we care about is to once and forever solve the old mystery of osteoarthritis to bring back joy to the lives of our patients.”

The understanding that the root cause of osteoarthritis lies in mechanical factors has led Allegro to innovate in a remarkable way.

It has designed injectable nanotechnology that strengthens the synovial fluid and restores the joint’s shock-absorbing capabilities. This breakthrough results in immediate relief for patients, allowing them to regain mobility and alleviating their pain, enabling them to move freely and comfortably, akin to how a teenager might.

Allegro’s approach to tackling osteoarthritis is distinct and innovative, utilizing proprietary nanotechnology to develop unique particles. These particles, designed in a 3D shape, have the ideal geometrical model to absorb shocks and provide lubrication. This inventive approach is a beacon of hope for countless individuals suffering from osteoarthritis, offering them the prospect of a life free from the constraints of pain and discomfort.

This groundbreaking asset contains a rich pipeline in product ready to attack other large pathologies with unmet clinical needs, both standalone and in combination with other therapies.

At the helm of this endeavor is a dynamic leadership team. Jorg Schelfhout, an experienced researcher in regenerative biopolymers, and Lucas Decuypere, a serial life sciences entrepreneur, provide the guidance and vision to drive innovation. They have joined forces with prominent biotech investor Annie Vereecken, Noshaq, and key opinion leaders, including Professor Dr. Frank Luyten (ex-Tigenix) and Professor Dr. Yves Henrotin.

Under their guidance, Allegro has successfully completed preclinical studies on rodents and equine models, laying the groundwork for human trials that have been fast-tracked due to excellent preclinical results.

The upcoming inauguration of the state-of-the-art laboratory and cleanroom facilities in Liège, Belgium, marks a significant step toward scaling its innovative research to eliminate osteoarthritis.

Its steadfast determination and innovative methods promise to drastically improve the lives of numerous individuals who suffer from this ailment, granting them the opportunity to regain the pleasures of a pain-free existence.

Allegro’s team is on a mission of utmost urgency—to make osteoarthritis a relic of the past.